|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06BA12
|
|
gptkbp:brand
|
gptkb:Vyvanse
Elvanse (Europe)
|
|
gptkbp:CASNumber
|
608137-32-3
|
|
gptkbp:chemicalFormula
|
C15H25N3O
|
|
gptkbp:contraindication
|
concurrent use of MAO inhibitors
known hypersensitivity to amphetamines
|
|
gptkbp:controlledSubstanceSchedule
|
true
|
|
gptkbp:developedBy
|
gptkb:New_River_Pharmaceuticals
|
|
gptkbp:drugClass
|
amphetamine
stimulant
|
|
gptkbp:eliminatedIn
|
urine
|
|
gptkbp:form
|
capsule
chewable tablet
|
|
gptkbp:genericName
|
gptkb:lisdexamfetamine
|
|
gptkbp:halfLife
|
about 12 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vyvanse
|
|
gptkbp:legalStatus
|
prescription only
Schedule II controlled substance (US)
|
|
gptkbp:manufacturer
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:marketedAs
|
2007
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
prodrug of dextroamphetamine
|
|
gptkbp:metabolism
|
hydrolyzed to dextroamphetamine
|
|
gptkbp:notRecommendedFor
|
children under 6 years old
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adolescents
adults
children
|
|
gptkbp:prescriptionDrug
|
true
|
|
gptkbp:riskFactor
|
potential for abuse
cardiovascular events
psychiatric adverse reactions
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
weight loss
insomnia
dry mouth
irritability
decreased appetite
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
binge eating disorder
|
|
gptkbp:bfsParent
|
gptkb:Takeda
gptkb:Takeda_(Japan)
gptkb:Desoxyn
|
|
gptkbp:bfsLayer
|
6
|